AstraZeneca: Alzheimer drug trials discontinued

(CercleFinance.com) - Shares of AstraZeneca are down in early morning on Tuesday, after the company said it was discontinuing two Phase III trials for an experimental Alzheimer's disease drug developed with US partner Eli Lilly.


The decision was based on recommendations by an independent data monitoring committee, which concluded that the trials, both in early Alzheimer's disease and mild Alzheimer's disease dementia, were unlikely to meet their primary endpoints.

The primary endpoints of the trials were changes in several aspects of cognition for the patients.

AstraZeneca said the discontinuation of the clinical trials is not expected to have any significant impact on the company's financial guidance for 2018.

Shares in AstraZeneca are currently down 0.5% at 5,340 pence.

Copyright (c) 2018 CercleFinance.com. All rights reserved.